Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Evotec AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

24 Sep 2016 Reuters Investment Profile 12 $20.00

Wright Investors Service Comprehensive Report for Evotec AG

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

28 Sep 2016 Wright Reports 65 $75.00

"The Economy Matters" Report for EVTCY: the economy's impact on EVTCY's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score

"The Economy Matters"(r) Reports feature the powerful Economic Climate Rating and MacroRisk "Stoplight" to help you in your a...

27 Sep 2016 MacroRisk Analytics/EconomicInvestor 8 $25.00

ValuEngine Rating and Forecast Report for EVTCY

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

25 Sep 2016 ValuEngine, Inc. 11 $25.00

EVOTEC AG ADS (EVTCY=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

24 Sep 2016 Pechala's Reports 2 $25.00

Evotec AG (EVT) - Financial and Strategic SWOT Analysis Review

Evotec AG (EVT) - Financial and Strategic SWOT Analysis Review Summary Evotec AG (Evotec) is a drug discovery alliance and de...

19 Sep 2016 GlobalData 158 $300.00

Is Evotec AG the Safe Haven Investors Seek?

23 Aug 2016 Sadif Analytics Prime 12 $25.00

EVOTEC - SOLID H116, 2016 EBITDA GUIDANCE UPPED

Evotec delivered its Q216 and full H116 results last week, with sales largely in line with our expectations, while profits we...

16 Aug 2016 Edison Investment Research 6 $10.00

H1/16 sehr expansiv – Schätzungsanpassung

Die Erlöse in beiden Segmenten stiegen im H1/16 sehr kräftig (originär: +16 %). Meilensteinzahlungen, Lizenzen etc. (€ 7,0 Mi...

11 Aug 2016 EQUI.TS 4 $10.00

EVOTEC - HEALTHY CASH FLOWS IN THE FUTURE

Evotec operates a hybrid business model and offers a unique risk-reward profile for investors, with steady growth from its EV...

29 Jun 2016 Edison Investment Research 13 $10.00